Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...

Market News Wall Street ended lower on Tuesday as investors digested Mary Daly's remarks during a meeting at New York University, regarding interest rates. Market participants also evaluated Q3 ...